

Ranibizumab

for treating age-related macular degeneration, diabetic macular oedema and retinal vein occlusion

Technology Guidance from the MOH Drug Advisory Committee

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

- ✓ Ranibizumab 1.65 mg/0.165 ml pre-filled syringe and 2.3 mg/0.23 ml solution for injection as an alternative to intravitreal bevacizumab for treating adults with visual impairment due to:
 - neovascular (wet) age-related macular degeneration;
 - diabetic macular oedema; and
 - macular oedema secondary to central or branch retinal vein occlusion

in view of an acceptable price proposal from the manufacturer.

Subsidy status

Ranibizumab is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications.

About the Agency

The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidance, and education.

As the national HTA agency, ACE conducts evaluations to inform government subsidy decisions for treatments, diagnostic tests and vaccines, and produces guidance for public hospitals and institutions in Singapore.

This guidance is based on the evidence available to the MOH Drug Advisory Committee as at 18 Aug 2021. It is not, and should not be regarded as, a substitute for professional or medical advice. Please seek the advice of a qualified healthcare professional about any medical condition. The responsibility for making decisions appropriate to the circumstances of the individual patient remains with the healthcare professional.

Find out more about ACE at www.ace-hta.gov.sg/about

© Agency for Care Effectiveness, Ministry of Health, Republic of Singapore

All rights reserved. Reproduction of this publication in whole or in part in any material form is prohibited without the prior written permission of the copyright holder. Requests to reproduce any part of this publication should be addressed to:

Chief HTA Officer (HTA)
Agency for Care Effectiveness
Email: ACE_HTA@moh.gov.sg

In citation, please credit the “Ministry of Health, Singapore” when you extract and use the information or data from the publication.